Meeting
2023 ASCO Annual Meeting
Characteristics and clinical outcome of BRCA germline mutation carriers with advanced breast cancer treated with PARP (poly ADP-ribose polymerase) inhibitors: A single institution experience.
Authors
Fatma Nihan Akkoc Mustafayev
University of Texas, MD Anderson Cancer Center, Houston, TX
Fatma Nihan Akkoc Mustafayev , Mark Munsell , Angelica M. Gutierrez-Barrera , Clinton Yam , Rachel M. Layman , Banu Arun
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Hereditary Cancer
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Hereditary Cancer Syndromes
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 10587)
DOI
10.1200/JCO.2023.41.16_suppl.10587
Abstract #
10587
Poster Bd #
220
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
First Author: June Evelyn Jeon
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The identification of reversion mutations in patients with advanced pancreatic cancer and germline or somatic BRCA or PALB2 variants who were treated with maintenance rucaparib.
First Author: Timothy J Brown
Poster
2022 ASCO Annual Meeting
BRCA reversion mutations mediated by microhomology-mediated end joining (MMEJ) as a mechanism of resistance to PARP inhibitors in ovarian and breast cancer.
First Author: Natalia Lukashchuk
Poster
2022 ASCO Annual Meeting
Comprehensive whole-exome and transcriptome profiling to identify actionable alterations associated with response to PARP inhibitors in breast cancer.
First Author: Susan M. Dombrowski